While the biotech investment scene in Europe has slowed somewhat following a COVID-19 funding boom in 2021, a new report from PitchBook suggests venture capital firms looking at opportunities across the pond could soon have more cash to spare.

Venture capital funding into biopharma rose to $9.2 billion across 215 deals in the second quarter of this year, reaching the highest funding level since the same quarter in 2022.

BioAge Labs has appointed former GSK CEO Jean-Pierre Garnier as chair of its board of directors, bringing the pharma veteran back into the anti-aging space 16 years after he made a big bet on the sector.

After raising $213 million in 2023—one of the year’s largest private biotech rounds—Tome Biosciences is making cuts.

On the heels of a June 17 paper showing a small molecule’s ability to declutter pathological protein buildups in the brain, researchers from the University of California, San Diego (UCSD) and the University of Pennsylvania have received a $6.9 million grant from the National Institute on Aging to prepare the drug for clinical trials.

BridgeBio Pharma is once again spinning out a chunk of its pipeline, this time offloading a handful of early-stage genetic disease programs to a new company called GondolaBio.

Cancer diagnostics startup PreciseDx picked up $20.7 million in series B funding as it ramps up commercialization efforts for its AI-based breast cancer risk assessment.

Medtech startups fared well in the second quarter with investment activity on track to surpass last year and venture capital exits are on the rise, according to PitchBook’s latest sector report.

Pathalys Pharma has brought in $105 million via a series B fundraise that the kidney-disease-focused biotech will use to take its lead candidate through the final stages of clinical development.

Denmark’s Adcendo is the latest biotech to go big for an antibody-drug conjugate (ADC) deal, signing off on $1 billion in biobucks to get the ex-China rights to a preclinical candidate from Multitude Therapeutics.